These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 23364275)

  • 21. Relationship between oestrogen receptor status and proliferation in predicting response and long-term outcome to neoadjuvant chemotherapy for breast cancer.
    Jones RL; Salter J; A'Hern R; Nerurkar A; Parton M; Reis-Filho JS; Smith IE; Dowsett M
    Breast Cancer Res Treat; 2010 Jan; 119(2):315-23. PubMed ID: 19247830
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Ki-67 as a prognostic molecular marker in routine clinical use in breast cancer patients.
    Wiesner FG; Magener A; Fasching PA; Wesse J; Bani MR; Rauh C; Jud S; Schrauder M; Loehberg CR; Beckmann MW; Hartmann A; Lux MP
    Breast; 2009 Apr; 18(2):135-41. PubMed ID: 19342238
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Digital imaging in the immunohistochemical evaluation of the proliferation markers Ki67, MCM2 and Geminin, in early breast cancer, and their putative prognostic value.
    Joshi S; Watkins J; Gazinska P; Brown JP; Gillett CE; Grigoriadis A; Pinder SE
    BMC Cancer; 2015 Jul; 15():546. PubMed ID: 26205655
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Flow cytometry vs. Ki67 labelling index in breast cancer: a prospective evaluation of 181 cases.
    Martínez-Arribas F; Núñez MJ; Piqueras V; Lucas AR; Sánchez J; Tejerina A; Schneider J
    Anticancer Res; 2002; 22(1A):295-8. PubMed ID: 12017306
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Phosphohistone H3 outperforms Ki67 as a marker of outcome for breast cancer patients.
    Gerring Z; Pearson JF; Morrin HR; Robinson BA; Harris GC; Walker LC
    Histopathology; 2015 Oct; 67(4):538-47. PubMed ID: 25728258
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of the effect of different techniques for measurement of Ki67 proliferation on reproducibility and prognosis prediction accuracy in breast cancer.
    Gudlaugsson E; Skaland I; Janssen EA; Smaaland R; Shao Z; Malpica A; Voorhorst F; Baak JP
    Histopathology; 2012 Dec; 61(6):1134-44. PubMed ID: 22963617
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Breast cancer stromal elastosis is associated with mammography screening detection, low Ki67 expression and favourable prognosis in a population-based study.
    Chen Y; Klingen TA; Wik E; Aas H; Vigeland E; Liestøl K; Garred Ø; Mæhlen J; Akslen LA; Lømo J
    Diagn Pathol; 2014 Dec; 9():230. PubMed ID: 25522915
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The utility of mitotic index, oestrogen receptor and Ki-67 measurements in the creation of novel prognostic indices for node-negative breast cancer.
    Clahsen PC; van de Velde CJ; Duval C; Pallud C; Mandard AM; Delobelle-Deroide A; van den Broek L; van de Vijver MJ
    Eur J Surg Oncol; 1999 Aug; 25(4):356-63. PubMed ID: 10419704
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Membranous and cytoplasmic staining of Ki67 is associated with HER2 and ER status in invasive breast carcinoma.
    Faratian D; Munro A; Twelves C; Bartlett JM
    Histopathology; 2009 Jan; 54(2):254-7. PubMed ID: 19207951
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Predictive value of tumor Ki-67 expression in two randomized trials of adjuvant chemoendocrine therapy for node-negative breast cancer.
    Viale G; Regan MM; Mastropasqua MG; Maffini F; Maiorano E; Colleoni M; Price KN; Golouh R; Perin T; Brown RW; Kovács A; Pillay K; Ohlschlegel C; Gusterson BA; Castiglione-Gertsch M; Gelber RD; Goldhirsch A; Coates AS;
    J Natl Cancer Inst; 2008 Feb; 100(3):207-12. PubMed ID: 18230798
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Clinicopathological and biological features of breast cancer in young females and their relationship with prognosis].
    Meng J; Lang RG; Fan Y; Fu L
    Zhonghua Zhong Liu Za Zhi; 2007 Apr; 29(4):284-8. PubMed ID: 17760256
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Studies of the potential utility of Ki67 as a predictive molecular marker of clinical response in primary breast cancer.
    Assersohn L; Salter J; Powles TJ; A'hern R; Makris A; Gregory RK; Chang J; Dowsett M
    Breast Cancer Res Treat; 2003 Nov; 82(2):113-23. PubMed ID: 14692655
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immunohistochemical expression of p53, nm23-HI, Ki67 and DNA ploidy: correlation with lymph node status and other clinical pathologic parameters in breast cancer.
    Midulla C; De Iorio P; Nagar C; Pisani T; Cenci M; Valli C; Nofroni I; Vecchione A
    Anticancer Res; 1999; 19(5B):4033-7. PubMed ID: 10628350
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Expression correlation of Ki67 to P53,VEGF,and C-erbB-2 genes in breast cancer and their clinical significances].
    Li BJ; Zhu ZH; Wang JY; Hou JH; Zhao JM; Zhang PY; Yao GY; Wang X; Long H; Yang MT; Rong TH
    Ai Zheng; 2004 Oct; 23(10):1176-9. PubMed ID: 15473930
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Proliferation marker Ki-67 in early breast cancer.
    Urruticoechea A; Smith IE; Dowsett M
    J Clin Oncol; 2005 Oct; 23(28):7212-20. PubMed ID: 16192605
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tumour-related factors and prognosis in breast cancer detected by screening.
    Olsson A; Borgquist S; Butt S; Zackrisson S; Landberg G; Manjer J
    Br J Surg; 2012 Jan; 99(1):78-87. PubMed ID: 22068957
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparative prognostic value of Ki-67 and MIB-1 proliferation indices in breast cancer.
    Veronese SM; Maisano C; Scibilia J
    Anticancer Res; 1995; 15(6B):2717-22. PubMed ID: 8669852
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prediction of clinical outcome from primary tamoxifen by expression of biologic markers in breast cancer patients.
    Chang J; Powles TJ; Allred DC; Ashley SE; Makris A; Gregory RK; Osborne CK; Dowsett M
    Clin Cancer Res; 2000 Feb; 6(2):616-21. PubMed ID: 10690547
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Proliferation evaluation by measuring Ki67 in breast neoplasms].
    Vincent-Salomon A
    Ann Pathol; 2011 Nov; 31(5 Suppl):S57-9. PubMed ID: 22054462
    [No Abstract]   [Full Text] [Related]  

  • 40. Adjuvant sequencing of tamoxifen and anastrozole is superior to tamoxifen alone in postmenopausal women with low proliferating breast cancer.
    Bago-Horvath Z; Rudas M; Dubsky P; Jakesz R; Singer CF; Kemmerling R; Greil R; Jelen A; Böhm G; Jasarevic Z; Haid A; Gruber C; Pöstlberger S; Filipits M; Gnant M;
    Clin Cancer Res; 2011 Dec; 17(24):7828-34. PubMed ID: 21998336
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.